2023
Chick chorioallantoic membrane (CAM) assay for the evaluation of the antitumor and antimetastatic activity of platinum-based drugs in association with the impact on the amino acid metabolism
MITREVSKA, Katerina, Miguel Angel Merlos RODRIGO, Natalia CERNEI, Hana MICHALKOVA, Zbynek SPLICHAL et. al.Základní údaje
Originální název
Chick chorioallantoic membrane (CAM) assay for the evaluation of the antitumor and antimetastatic activity of platinum-based drugs in association with the impact on the amino acid metabolism
Autoři
MITREVSKA, Katerina, Miguel Angel Merlos RODRIGO, Natalia CERNEI, Hana MICHALKOVA, Zbynek SPLICHAL, David HYNEK, Ondrej ZITKA, Zbynek HEGER, Pavel KOPEL, Vojtech ADAM a Vedran MILOSAVLJEVIC (garant)
Vydání
Materials Today Bio, AMSTERDAM, Elsevier, 2023, 2590-0064
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
20601 Medical engineering
Stát vydavatele
Nizozemské království
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 8.200 v roce 2022
Kód RIV
RIV/00216224:90242/23:00133762
Organizační jednotka
CIISB III
UT WoS
000931958900001
Klíčová slova anglicky
Platinum nanoparticles; Cisplatin; CAM assay; Breast cancer; Amino acids metabolism; TCA cycle
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 11. 4. 2024 23:14, Mgr. Michal Petr
Anotace
V originále
The combination of in ovo and ex ovo chorioallantoic membrane (CAM) assay provides an excellent platform which extends its relevance in studying carcinogenesis to the field of screening of anticancer activity of platinum nanoparticles (PtNPs) and further study of the amino acids' fluctuations in liver and brain. PtNPs are promising candidates for replacing cisplatin (CDDP); however, insufficient data of their antitumor efficiency and activity on the cancer-related amino acid metabolism are available, and the assessment of the in vivo performance has barely scratched the surface. Herein, we used CAM assay as in vivo model for screening of novel therapeutic modalities, and we conducted a comparative study of the effects of CDDP and polyvinylpyrrolidone coated PtNPs on MDA-MB-231 breast cancer xenograft. PtNPs showed a higher efficiency to inhibit the tumor growth and metastasis compared to CDDP. The amino acids profiling in the MDA-MB-231 cells revealed that the PtNPs had an overall depleting effect on the amino acids content. Noteworthy, more side effects to amino acid metabolism were deduced from the depletion of the amino acids in tumor, brain, and liver upon CDDP treatment. Different sets of enzymes of the tricarboxylic acid (TCA) cycle were targeted by PtNPs and CDDP, and while mRNA encoding multiple enzymes was downregulated by PtNPs, the treatment with CDDP affected only two TCA enzymes, indicating a different mechanism of action. Taken together, CAM assay represents and invaluable model, demonstrating the PtNPs capability of repressing angiogenesis, decrease amino acid contents and disrupt the TCA cycle.
Návaznosti
90242, velká výzkumná infrastruktura |
|